University of Calgary at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Calgary brings 8 presentations to ASH 2026 in New Orleans. Its program spans myeloma, leukemia and inherited blood disorders. Research covers aberrant BCMA splicing as a route to resistance, CRISPR therapy eligibility in sickle cell disease and bleeding disorders of unknown cause.
| Organization | ASH 2026 Attendance |
|---|---|
University of Calgary Calgary, Canada | |
Public research university in Calgary, Alberta, with a medical school. | Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Poster Sat Dec 12 5:30pm–7:30pm Oral Sun Dec 13 4:30pm–6:00pm Poster Sun Dec 13 6:00pm–8:00pm Oral Mon Dec 14 2:45pm–4:15pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Find decision makers at University of Calgary
Tell us what you sell and we’ll find the people at University of Calgary most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction